Redhill Biopharma Ltd (RDHL) ADR Each Representing 1000 Ord Shares SPON
Sell:$5.80Buy:$5.99
$0.26
(4.29%)
- This stock can be held in a
Stocks and Shares ISA
SIPP$0.26
(4.29%)$0.26
(4.29%)Company Information
About this company
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Key people
Key facts
- EPIC-
- LocationIsrael
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS7574683014
- Market cap$7.85m
- Employees53
- Shares in issue314.79m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.